Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Medexus Pharmaceuticals Inc. Stock

Equities

MDP

CA58410Q2036

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:58 2025-02-11 pm EST 		5-day change 1st Jan Change
3.250 CAD +3.83% Intraday chart for Medexus Pharmaceuticals Inc. -16.02% -6.07%
Feb. 06 Medexus Pharmaceuticals Inc., Q3 2025 Earnings Call, Feb 06, 2025
Feb. 05 Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI

Valuation: Medexus Pharmaceuticals Inc.

Capitalization 105M 73.28M 70.83M 66.86M 58.99M 6.36B 116M 796M 295M 2.64B 275M 269M 11.16B P/E ratio 2025 *
64.8x
P/E ratio 2026 * -27.9x
Enterprise value 105M 73.28M 70.83M 66.86M 58.99M 6.36B 116M 796M 295M 2.64B 275M 269M 11.16B EV / Sales 2025 *
0.67x
EV / Sales 2026 * 0.7x
Free-Float
69.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data

Chart: Medexus Pharmaceuticals Inc.

Dynamic Chart

Latest news: Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc., Q3 2025 Earnings Call, Feb 06, 2025 Feb. 06
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 Feb. 05 CI
Medexus Pharmaceuticals and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv in Ontario, Canada Feb. 04 CI
Medexus Pharmaceuticals Prices $30-Million Marketed Share Offering Jan. 28 MT
Medexus Pharmaceuticals Launches Overnight Marketed Stock Offering; Shares Fell 6.5% Today Jan. 27 MT
Medexus up 30% as Receives FDA Approval For Tresulfan Injection Jan. 22 MT
Medexus Pharma Shares Higher on FDA Approval for Grafapex Jan. 22 DJ
Medexus Pharmaceuticals Inc. Announces FDA Approval of GRAFAPEX for Injection Jan. 22 CI
Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Three-Month Period Ended December 31, 2024 Jan. 22 CI
Medexus and pan-Canadian Pharmaceutical Alliance Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada Nov. 18 CI
Medexus Pharmaceuticals Inc., Q2 2025 Earnings Call, Nov 08, 2024 Nov. 08
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 Nov. 07 CI
Medexus Pharmaceuticals Inc. - Shareholder/Analyst Call 24-09-19
More news

Last Transcript: Medexus Pharmaceuticals Inc.

Logo Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc., Q3 2025 Earnings Call, Feb 06, 2025
Feb. 06
More transcripts

Analysts' recommendations: Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 24-02-09 MT
Medexus Pharmaceuticals Buy Rating Maintained by Stifel GMP as Drug Approvals Awaited; Price Target Lowered to C$11.00 22-08-10 MT
Medexus Pharmaceuticals Initiated at Outperform With $5.50 Target at Raymond James 22-02-22 MT
More recommendations

Press Releases: Medexus Pharmaceuticals Inc.

Canadian Investment Regulatory Organization Trade Resumption - MDP Feb. 06 AQ
Canadian Investment Regulatory Organization Trading Halt - MDP Feb. 06 AQ
Medexus Pharmaceuticals : Management Discussion & Analysis Q3 2025 Feb. 05 PU
Medexus Pharmaceuticals : Financial Statements Q3 2025 Feb. 05 PU
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States Feb. 05 NE
More press releases

Quotes and Performance

1 day+3.83%
1 week-16.02%
Current month-15.58%
1 month-19.55%
3 months+60.10%
6 months+35.98%
Current year-6.07%
More quotes

Course Extremes

1 week
2.90
Extreme 2.9
3.69
1 month
2.90
Extreme 2.9
5.56
Current year
2.90
Extreme 2.9
5.56
1 year
1.47
Extreme 1.47
5.56
3 years
0.88
Extreme 0.88
5.56
5 years
0.88
Extreme 0.88
9.75
10 years
0.88
Extreme 0.88
9.75
More quotes

Managers and Directors: Medexus Pharmaceuticals Inc.

Director TitleAgeSince
Kenneth d’Entremont CEO
 Chief Executive Officer - 2018-12-16
Brendon Buschman DFI
 Director of Finance/CFO - 2024-06-27
Richard Labelle COO
 Chief Operating Officer - 2014-02-17
Manager TitleAgeSince
Michael Mueller CHM
 Chairman 65 2023-04-10
Benoit Gravel BRD
 Director/Board Member - 2017-09-21
Kenneth d’Entremont BRD
 Director/Board Member - 2018-10-15
More insiders

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
MEDEXUS PHARMACEUTICALS INC. Stock Medexus Pharmaceuticals Inc.
+3.83%-16.02%+73.80%-2.40% 73.28M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.45%+4.71%+16.87%+266.93% 779B
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.23%+1.72%-0.40%-6.90% 376B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-2.52%-5.60%-29.59%+81.87% 370B
ABBVIE INC. Stock AbbVie Inc.
+0.78%+0.99%+10.20%+35.08% 339B
ROCHE HOLDING AG Stock Roche Holding AG
+0.36%-0.24%+27.74%-15.08% 254B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.41%+4.94%+22.89%+39.31% 224B
MERCK & CO., INC. Stock Merck & Co., Inc.
+0.16%-4.63%-31.02%+12.92% 219B
NOVARTIS AG Stock Novartis AG
-0.84%-0.96%+11.35%+23.29% 212B
AMGEN INC. Stock Amgen Inc.
+0.63%+2.64%+1.90%+30.00% 159B
Average -0.22%-0.03%+10.37%+46.50% 293.16B
Weighted average by Cap. -0.89%+2.84%+4.63%+90.39%
See all sector performances

Financials

2025 *2026 *
Net sales 155M 109M 105M 99.15M 87.47M 9.43B 173M 1.18B 438M 3.92B 407M 399M 16.55B 149M 104M 101M 95.1M 83.9M 9.04B 166M 1.13B 420M 3.76B 391M 383M 15.87B
Net income 741K 518K 500K 472K 417K 44.93M 822K 5.62M 2.09M 18.67M 1.94M 1.9M 78.84M -4.27M -2.99M -2.89M -2.72M -2.4M -259M -4.74M -32.44M -12.04M -108M -11.19M -10.97M -455M
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Employees
82
Sector
Pharmaceuticals
Calendar
2025-06-30 - Q4 2025 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-02-11 3.250 $ +3.83% 60,570
25-02-10 3.130 $ -2.49% 150,059
25-02-07 3.210 $ +5.25% 209,889
25-02-06 3.050 $ -19.53% 608,952
25-02-05 3.790 $ -2.07% 106,129

Delayed Quote Toronto S.E., February 11, 2025 at 03:59 pm EST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.250CAD
Average target price
6.493CAD
Spread / Average Target
+99.78%
Consensus
Profit revisions
Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MDP Stock